Jasmiel
Product Images NDC 53002-1783

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Jasmiel (NDC 53002-1783). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Drospirenone Fig1)

A logarithmic scale forest plot showing VTE risk with Yasmin relative to LNG-containing COCs from various studies, including prospective and retrospective cohort, case-control, and non-fatal idiopathic cases only. The figure displays hazard ratios, rate ratios, and odds ratios with confidence intervals for multiple studies, illustrating risk comparisons for venous thromboembolism (VTE).*

FDA Label Image

Figure 2 (Drospirenone Fig2)

A horizontal bar chart titled "Likelihood of Developing a VTE" showing the estimated number of women with a blood clot per 10,000 woman years for four groups: Non-Pregnant Non-COC user (1 to 5), COC-User (3 to 9), Pregnancy (5 to 20), and Postpartum (12 weeks only) (40 to 65). The x-axis represents the number of women with a blood clot per 10,000 woman years, and a note explains the pregnancy data calculation.*

FDA Label Image

Figure3 (Drospirenone Fig3)

An illustration depicting the relative effectiveness of various birth control methods ranked by number of pregnancies per 100 women in one year. Methods range from fewer than 1 pregnancy (implants, injections, intrauterine devices, sterilization) to 85 or more pregnancies with no birth control. Intermediate methods include birth control pills, skin patch, vaginal ring with hormones, condoms, diaphragm, abstinence during fertile days, spermicide, and withdrawal.*

FDA Label Image

Figure4 (Drospirenone Fig4)

Medication blister card for Jasmiel (Propranolol and Ethinyl Estradiol Tablets, USP) showing a 28-day dosing schedule arranged in four rows by day of the week with each dose represented by a circular tablet cavity. The strength is 3 mg/0.02 mg. Labeler is RPK Pharmaceuticals, Inc. The card is designed to track daily medication intake through the weekly layout.*

FDA Label Image

Figure5 (Drospirenone Fig5)

A bar chart comparing the number of women with blood clots per 10,000 women years across four groups: Non-Pregnant Non-COC users, COC users, Pregnant women, and Postpartum (12 weeks only). The chart shows ranges of clot incidence with postpartum women having the highest rates and non-pregnant non-COC users the lowest.*

FDA Label Image

Chemical Str (Drospirenone Str)

Chemical structure diagram displaying two active ingredients, Drospirenone and Ethinyl estradiol, commonly used in combination oral contraceptives.*

FDA Label Image

Label Image (Lbl530021783)

Jasmiel tablets 28-day supply blister card, labeled by RPK Pharmaceuticals, Inc. The label instructs to take 1 tablet daily as directed, indicating this is an oral contraceptive. The packaging includes patient and prescriber information fields, lot and expiration dates, and NDC barcode and number 53002-1783. The product is identified as a 1-month pack.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.